Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses
Checkpoint blockade with antibodies specific for cytotoxic T lymphocyte-associated protein (CTLA)-4 or programmed cell death 1 (PDCD1; also known as PD-1) elicits durable tumor regression in metastatic cancer, but these dramatic responses are confined to a minority of patients. This suboptimal outco...
Similar Items
-
Order of administration of combination cytokine therapies can decouple toxicity from efficacy in syngeneic mouse tumor models
by: Adrienne Rothschilds, et al.
Published: (2019-05-01) -
Temporally Programmed CD8α[superscrip +] DC Activation Enhances Combination Cancer Immunotherapy
by: Szeto, Gregory L., et al.
Published: (2017) -
Roles for Innate Immunity in Combination Immunotherapies
by: Moynihan, Kelly Dare, et al.
Published: (2018) -
High-throughput quantitation of inorganic nanoparticle biodistribution at the single-cell level using mass cytometry
by: Bekdemir, Ahmet, et al.
Published: (2017) -
Synergistic Innate and Adaptive Immune Response to Combination Immunotherapy with Anti-Tumor Antigen Antibodies and Extended Serum Half-Life IL-2
by: Surana, Rishi, et al.
Published: (2016)